Your browser doesn't support javascript.
loading
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
Yang, Mingming; Kondo, Toru; Talebi, Atefeh; Jhund, Pardeep S; Docherty, Kieran F; Claggett, Brian L; Vaduganathan, Muthiah; Bachus, Erasmus; Hernandez, Adrian F; Lam, Carolyn S P; Inzucchi, Silvio E; Martinez, Felipe A; de Boer, Rudolf A; Kosiborod, Mikhail N; Desai, Akshay S; Køber, Lars; Ponikowski, Piotr; Sabatine, Marc S; Solomon, Scott D; McMurray, John J V.
Afiliación
  • Yang M; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Kondo T; Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Talebi A; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Jhund PS; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Docherty KF; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Claggett BL; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Vaduganathan M; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Bachus E; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Hernandez AF; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Lam CSP; Late-Stage Development, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
  • Inzucchi SE; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
  • Martinez FA; National Heart Centre Singapore and Duke-National University of Singapore, Singapore.
  • de Boer RA; Yale School of Medicine, New Haven, CT, USA.
  • Kosiborod MN; Universidad Nacional de Córdoba, Córdoba, Argentina.
  • Desai AS; Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Køber L; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA.
  • Ponikowski P; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Sabatine MS; Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Solomon SD; Medical University, Clinical Military Hospital, Wroclaw, Poland.
  • McMurray JJV; TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Eur J Heart Fail ; 26(7): 1524-1538, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38700986
ABSTRACT

AIMS:

Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores. METHODS AND

RESULTS:

We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively. Patients reporting higher (better) EQ-5D-5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator-reported (New York Heart Association class) and patient-self-reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N-terminal pro-B-type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ-5D-5L VAS scores had better

outcomes:

the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72-0.91) in Q2, 0.74 (0.65-0.84) in Q3, and 0.62 (0.54-0.72) in Q4. The risk of each component of the composite outcome, and all-cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ-5D-5L VAS and index scores across the range of ejection fraction.

CONCLUSIONS:

Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Volumen Sistólico / Compuestos de Bencidrilo / Glucósidos / Insuficiencia Cardíaca Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Volumen Sistólico / Compuestos de Bencidrilo / Glucósidos / Insuficiencia Cardíaca Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido